Exploring miR-21 Knock-Out Using CRISPR/Cas as a Treatment for Lung Cancer
Genes · 2025
DOI: 10.3390/genes16020133 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2025. Verfasst von Patricia Lara und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biopathology and Regenerative Medicine (IBIMER), Center of Biomedical Research (CIBM), University of Granada, 18100 Granada, Spain. Hauptthemen laut MEDLINE: MicroRNAs, Lung Neoplasms, CRISPR-Cas Systems. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the CTS-107 Group.
Abstract (Originalsprache)
Background
Lung cancer is a leading cause of cancer-related deaths worldwide. Its high incidence and poor prognosis demonstrate the need to investigate new therapies. The PI3K/AKT pathway is activated in carcinogenic processes such as invasion, proliferation, and drug resistance. MiR-21 is a microRNA overexpressed in numerous types of cancer and which activates PI3K/AKT pathway by down-regulating its main targets, PTEN and PDCD4. CRISPR is a revolutionary gene-editing technology that allows genes to be deleted. The aim of this study was to use CRISPR/Cas9 technology as an option to reduce carcinogenic and drug resistance processes by eliminating miR-21.
Methods
CRISPR/Cas9 was used to knock out miR-21 (miR-21 KO) in A549 lung cancer cells and thus reverse the carcinogenic processes activated by miR-21 overexpression. Furthermore, the effect of miR-21 KO on drug resistance was studied, choosing the main chemotherapeutic agents used for the treatment of lung cancer: gemcitabine, carboplatin, paclitaxel, and oxaliplatin. Results: miR-21 KO A549 cells exhibited a reduction in proliferation, migration, and colony formation compared to A549 cells. In contrast, the expression of PTEN and PDCD4 increased in miR-21 KO A549 cells. Furthermore, miR-21 KO A549 cells showed a decrease in the IC50 of the drugs used for the treatment of lung cancer: gemcitabine, carboplatin, paclitaxel, and oxaliplatin.
Conclusions
Based on these results, miR-21 knock-out using CRISPR/Cas could be a promising strategy for the treatment of lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biopathology and Regenerative Medicine (IBIMER), Center of Biomedical Research (CIBM), University of Granada, 18100 Granada, Spain.
- GENYO, Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government PTS Granada, 18016 Granada, Spain.
- Department of Medicinal & Organic Chemistry and Excellence Research Unit of "Chemistry Applied to Biomedicine and the Environment", Faculty of Pharmacy, University of Granada, Campus de Cartuja, 18071 Granada, Spain.
- Instituto de Investigación Biosanitaria de Granada, ibs. GRANADA, 18014 Granada, Spain.
- Departamento de Bioquímica y Biología Molecular e Inmunología, Facultad de Medicina, Universidad de Granada, 18071 Granada, Spain.
- Department of Anatomy and Embryology, Faculty of Medicine, University of Granada, 18016 Granada, Spain.
ORCID-Profile: Francisco Martín, Ana R Rama
Förderung
- the CTS-107 Group
Zitieren
APA
Lara, P., Aguilar-González, A., Martín, F., Mesas, C., Moreno, J., & Rama, A. R. (2025). Exploring miR-21 Knock-Out Using CRISPR/Cas as a Treatment for Lung Cancer. Genes. https://doi.org/10.3390/genes16020133
Vancouver
Lara P, Aguilar-González A, Martín F, Mesas C, Moreno J, Rama AR. Exploring miR-21 Knock-Out Using CRISPR/Cas as a Treatment for Lung Cancer. Genes. 2025. doi:10.3390/genes16020133
BibTeX
@article{Lara2025,
author = {Lara, Patricia and Aguilar-González, Araceli and Martín, Francisco and Mesas, Cristina and Moreno, Javier and Rama, Ana R},
title = {Exploring miR-21 Knock-Out Using CRISPR/Cas as a Treatment for Lung Cancer},
journal = {Genes},
year = {2025},
doi = {10.3390/genes16020133}
}
EUVIMED